Dimensional Fund Advisors
GANX icon

Dimensional Fund Advisors’s Gain Therapeutics GANX Stock Holding History

Dimensional Fund Advisors’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,886
Closed -$51.9K – 3407
2023
Q4 		$51.9K Sell
15,886
-933
-6% -$2.59K ﹤0.01% 3344
2023
Q3 		$54.3K Sell
16,819
-4,143
-20% -$15.7K ﹤0.01% 3374
2023
Q2 		$93.9K Buy
20,962
+2,355
+13% +$11.5K ﹤0.01% 3335
2023
Q1 		$89.7K Buy
18,607
+6,661
+56% +$27.2K ﹤0.01% 3317
2022
Q4 		$37 Buy
11,946
+4
+0% +$13 ﹤0.01% 3421
2022
Q3 		$39K Buy
+11,942
New +$44.9K ﹤0.01% 3431

Other funds holding GANX

DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors's GANX Position: Q1 2024 in Review

Dimensional Fund Advisors sold out of Gain Therapeutics (GANX) in Q1 2024, closing a stake of 15,886 shares — an estimated $51.9K sold.

Dimensional Fund Advisors first reported a position in GANX in Q3 2022 and held it in 6 quarters. The position peaked at $93.9K in Q2 2023. 26 funds tracked by Wall St. Rank hold GANX as of Q1 2024.

  • Dimensional Fund Advisors reported no remaining Gain Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Dimensional Fund Advisors sold 15,886 Gain Therapeutics shares in Q1 2024, an estimated $51.9K.
  • Dimensional Fund Advisors first reported a position in Gain Therapeutics in Q3 2022 and held it in 6 quarters.
  • Dimensional Fund Advisors's Gain Therapeutics position peaked at $93.9K in Q2 2023.
  • 26 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2024.

Based on Dimensional Fund Advisors's 13F filing for Q1 2024, filed 10 May 2024.